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Abstract 
It is a well-established fact that tumors up-regulate glucose consumption to meet 
increasing demands for rapidly available energy by switching to purely glycolytic mode 
of glucose metabolism. What is often neglected is that cytotoxic cells of the immune 
system also have increased energy demands and also switch to pure glycolysis when they 
are in an activated state. Moreover, while cancer cells can revert back to aerobic 
metabolism, rapidly proliferating cytotoxic lymphocytes are incapable of performing 
their function when adequate resources are lacking. Consequently, in the tumor 
microenvironment there must exist competition for the common resources between 
cancer cells and the cells of the immune system, which may drive a lot of the tumor-
immune dynamics. Proposed here is a model of tumor-immune-glucose interactions, 
formulated as a predator-prey-common resource type system, which allows to investigate 
possible dynamical behaviors that may arise as a result of competition for glucose, 
including tumor elimination, tumor dormancy and unrestrained tumor growth. 
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Introduction 
Immunoediting is the process whereby the immune system can alter, or ‘edit’, the 
progression of tumor growth. It has been proposed that the process of immunoediting 
consists of three distinct phases: elimination phase, when the cytotoxic cells of the 
immune system reduce tumor size, equilibrium, when tumor size is maintained at a 
constant level, and escape, when the tumor circumvents the immune response, as tumor 
cells develop resistance and start growing again (1-3). The process of tumor escape is 
believed to be driven by mutations, and specifically, by the eventual appearance and 
subsequent selection for non-immunogenic tumor clones (2). We propose that 
circumvention of the immune system and subsequent tumor escape is not necessarily a 
result of increased genomic instability but can be explained solely by competition for 
common resources between cancer and immune cells in the tumor microenvironment. 
It is a well-established fact that tumor cells can significantly up-regulate glucose 
consumption to meet the high energetic demands for cell survival and proliferation. 
Intriguingly, they frequently switch to fast but less efficient purely glycolytic mode of 
glucose metabolism even in the areas of ample oxygen supply, which yields 2 molecules 
of ATP compared to approximately 30 ATP that would have been obtained as a result of 
oxidative phosphorylation  (4-6).  Advantages of up-regulated glycolysis include not only 
significantly increased speed of access to the generated ATP but also the ability to divert 
glucose intermediates for new cell manufacturing  (7; 8). A switch to pure glycolysis as a 
primary mode of glucose metabolism is often accompanied by up to 30-fold increase in 
glucose uptake and over-expression of glucose transporters, such as GLUT-1 and SGLT-
1 (9) . Similarly, actively proliferating cytotoxic lymphocytes  also switch to purely 
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glycolytic mode of glucose metabolism, which is accompanied by a similar up-regulation 
of the expression of glucose transporters, such as GLUT-1 (10). Moreover, failure to 
increase glucose uptake during lymphocyte activation prevents cell growth and limits cell 
functionality, as cells deprived of adequate glucose supply cannot produce cytokines such 
as IFN-γ, which are required for effector function (11; 12). Therefore, it is not 
unreasonable to assume that in the tumor microenvironment there can exist competition 
for glucose between tumor and immune cells, and the outcome of this interaction would 
be determined by whichever cell type is the first to acquire access to glucose. This 
hypothesis relies specifically on the fact that T cells proliferate not only in the periphery 
but also in the tumor microenvironment (Thompson et al. 2010). 
These considerations allow to conceive of the following theoretical set-up: as the 
primary tumor grows, the cells inside it switch to glycolysis due to oxygen deprivation, 
establishing a glycolytic core, while the cells on the outside of the tumor may still 
continue using more energy efficient aerobic metabolism. Assuming sufficient tumor 
immunogenicity and functional immune response, actively proliferating immune cells 
that are attracted to the tumor cite are expected to be able to succeed in competition for 
glucose at this stage of the tumor-immune interaction, since, unlike aerobic cancer cells 
that they are coming in contact with, immune cells are using purely glycolytic mode of 
metabolism, which, as was pointed out above, is accompanied by significant upregulation 
of nutrient transporters. As a result of successful tumor ‘contraction’ by the immune 
cells, glycolytic core of the tumor could become exposed, and these glycolytic tumor 
cells can now actively compete with the immune cells for the available glucose. Should 
the immune cells not be able to succeed (if, for instance, selection for extremely up-
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regulated nutrient transporters was more severe in the oxygen-deprived tumor core than it 
was for the immune cells in their environment), then they will not be able to undergo 
clonal expansion, thus allowing the tumor to circumvent the immune system and continue 
growing. A schematic representation of the proposed scenario is given in Figure 1. 
 
Figure 1. Proposed scenario of metabolism-driven tumor escape. In the tumor 
microenvironment, glucose is taken up by cytotoxic lymphocytes that use glycolysis as a 
primary mode of metabolism, causing the tumor to contract and exposing its glycolytic 
core. The glycolytic tumor cells have up-regulated nutrients transporters, thus posing 
competition to immune cells for resources. Lymphocytes cannot proliferate unless their 
nutrient demands are met, which can allow tumor cells to circumvent immune response, 
leading to tumor escape. 
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We introduce a mathematical model in order to investigate whether such a 
behavior can indeed be realized using the most basic set of  assumptions about tumor-
immune-glucose interactions, as well as to study any other possible regimes that may 
arise in such a system. The proposed model is a 4-dimensional system of ordinary 
differential equations of the form predator-prey-common resource, where the cytotoxic 
lymphocytes are the predator, cancer cells are the prey, and glucose is the common 
resource. We hypothesize that depending on glucose availability we’ll be able to observe 
the escape phase of immunoediting, which will be driven purely by competition for 
resources in the tumor microenvironment. 
Model Description 
Proposed here is a conceptual mathematical model aimed to describe the 
dynamical interactions between a heterogeneous population of tumor cells (prey) and 
cytotoxic immune cells (predator), competing for glucose in the tumor microenvironment 
(the common resource). 
The population of tumor cells ( )T t  is divided into two subpopulations of aerobic 
and glycolytic cells such that ( ) ( ) ( )a gT t T t T t  . The dynamics of the two 
subpopulations is described by identical equations that differ solely in intrinsic parameter 
values. Tumor growth is assumed to be proportional to the amount of glucose that is 
available to the cells in the microenvironment, which is described by the term 
( )
1 (
(
)
)j j
T
G t
r T
b G
t
t
, where j=a represents aerobic cells and j=g represents glycolytic cells; 
this functional form was taken from classical models of consumer-resource interactions, 
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reviewed in Cantrell et al. (13). Tumor cells can die either naturally proportionally to 
( )j jT t  or they can be killed by cytotoxic lymphocytes ( )I t , which is accounted for by 
the term  
( ) / ( )
( )
( ) / ( )
j
j j
j
I t T t
e T t
s I t T t
; this functional form is taken from models describing 
tumor-immune interactions developed by de Pillis et al. (14; 15).  
Glucose ( )G t  is replenished from the blood stream at a constant rate 0G  and is 
consumed differentially by tumor cells  according to functional form 
( )
( )
1 ( )
j j
T
G t
d T t
b G t
 
and by immune cells 
( )
( )
1 ( )
I
I
G t
d I t
b G t
; since actively proliferating cytotoxic immune 
cells switch to glycolysis, we assume that 
I gd d ; the rate of glucose consumption by 
aerobic cells ar  however has been estimated to be up to 20-30 times lower (9). Glucose is 
also consumed by normal tissue, which in our model is accounted for by the term 
( )
1 ( )
G
N
G t
b G t


. We assume here that 1Nb  , which allows to approximate this term as 
( )GG t . 
Finally, cytotoxic immune cells are recruited to the tumor site at a rate 0 ( )i T t ; 
parameter 0i  can vary significantly depending on the degree of systemic immune 
stimulation or tumor-induced suppression; it can also be affected by various types of 
immunotherapy. Immune cells are assumed to die at some natural rate ( )I I t , which can 
also vary depending both on overall health of the patient and on various external stimuli, 
such as low-dose irradiation (16). Finally, expansion of cytotoxic immune cells depends 
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both proportionally to the number of tumor cells that have already been killed by the 
immune cells (14; 15), and proportionally to the amount of glucose available to the 
immune cells in tumor microenvironment. This restriction is imposed to account for the 
fact that due to their high energy demands, even fully activated cytotoxic immune cells 
cannot perform their function if they do not have access to sufficient amounts of glucose 
(10). 
The assumptions that were used in model formulation can be summarized as follows: 
1. Tumor population consists of aerobic and glycolytic cells.  
2. Glycolytic tumor cells grow faster but also deplete common resources faster (they 
have higher nutrient uptake rates). 
3. Glucose is depleted at different rates by tumor and immune cells; aerobic cells 
deplete it slower, glycolytic tumor cells and immune cells deplete it faster. 
4. Population of immune cells decays in the absence of tumor, since cytotoxic 
lymphocytes need co-stimulatory signals from tumor cells to enable them to take 
up glucose; otherwise they die by starvation. 
5. Expansion and functionality of immune cells is glucose-dependent: they cannot 
grow and perform their function if they do not have access to sufficient amounts 
of glucose. 
Taking all of these assumptions into account, we end up with the following 
system of ordinary differential equations: 
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Description of the parameters and sample values are given in Table 1. 
Results 
The goal of the numerical computations conducted for this model is to investigate 
whether we can observe the theoretically predicted cycle of metabolism-modulated 
immune escape given the simplest set of assumptions outlined in Figure 1, as well as to 
see what some of the other possible dynamical regimes there can be. We chose to focus 
on the effect of parameters 
 
i
0
 (systemic immune stimulation), 
 
e
j
 (effectiveness of tumor 
elimination by the immune system,  j = a,g ) and  
m
I
 (death rate of cytotoxic 
lymphocytes) on system dynamics because we believe that these parameters can, at least 
in theory, be manipulated in an experimental setting via various therapeutic interventions, 
such as chemo-, radiation and immunotherapy. 
Aerobic and glycolytic tumor cells can cooperate to defeat the immune system 
 9 
In the first set of simulations, we varied parameter 
 
i
0
 and were indeed able to 
observe the theoretically predicted cyclical dynamics. Other parameters were held 
constant at 
 
b
I
= b
T
= 0.9 , 
 
e
a
= e
g
= 0.1, 
 
r
a
= 0.1, 
 
r
g
=1.9r
a
,  s = 0.7,  
d
a
= 0.1, 
 
d
g
= d
I
= 2d
a
, 
 
m
a
= 0.01, 
 
m
g
= 3m
a
, 
 
G
0
=1, 
 
m
I
= 0.01, 
 
r
I
= 0.01,  T(0) = I(0) =C(0) =1, 
 
T
a
(0) = 0.1T . Parameter values were chosen based on the values provided in the validated 
mathematical models proposed by de Pillis et al. (14; 15); in other cases, parameter values 
were estimated based on theoretical considerations. It is important to emphasize that the 
primary purpose of the proposed model is to validate theoretical predictions, identify 
qualitative regimes that are possible within the described framework and to propose 
further research directions rather than to match predictions to specific pre-existing data. 
As we progressively increased parameter 
 
i
0
, we were able to observe the 
dynamical shift from tumor persistence (Figure 2a) to multiple cyclical regimes (Figure 
2b) to decrease in cycle number before tumor size stabilized at a low equilibrium value 
(Figure 2c) to equilibrium state achieved without any preceding cyclical dynamics 
(Figure 2d). 
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Figure 2. Different dynamical regimes that can be observed through progressively 
increasing parameter 
 
i
0
, which represents systemic immune stimulation. Some possible 
regimes that can be observed range from a) escape of a primarily aerobic tumor to b) 
sustained cyclical behavior described in Figure 1 to c) several iterations of cyclical 
behavior before bringing down tumor size to d) tumor control. 
 
Within this set of simulations we could observe that predicted cyclical dynamics 
can recur several times before the immune system brings down the overall tumor size. 
Moreover, as one can see, the composition of the tumor with respect to metabolic strategy 
can be different at different stages of the cycle: while in Figure 2a the tumor is composed 
primarily of aerobic cells, in Figure2c and d, the tumor is composed of glycolytic cells. 
The specifics of the dynamics that drive the oscillations can be observed in more 
detail in Figure 3a, which is a magnification of the dynamics shown in Figure2b: 
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Figure 3. Details underlying the dynamics of a) oscillations driven by glycolytic cancer 
cells ( 0.9Tb  , 0.1je  , 1.8g ar r , 0 2.1 4i e  ) and b) oscillations driven by aerobic 
cancer cells ( 0.2Tb  , 0.2je  , 2.8g ar r , 0 2.0 3i e  ). The first case corresponds to 
competition driven circumvention of immune surveillance; the second case corresponds 
to a variant of a classic predator-prey type system. 
 
We can observe that increase in the number of immune cells corresponds to 
decrease in the number of aerobic tumor cells. As tumor size decreases, so does the 
population of immune cells, since con-stimulatory molecules from tumor debris are 
necessary for clonal expansion of immune cells (this is accounted for by the last term in 
the equation for dL/dt).  As the population of immune cells decreases and stops utilizing 
glucose, its levels rise and it can now be then taken up by expanding glycolytic cells. This 
causes a sharp drop in glucose levels in the tumor microenvironment, preventing immune 
cells from proliferating, in this case not from lack of co-stimulation but from lack of 
resources necessary for clonal expansion.   
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In such a scenario, the dynamics can be interpreted as cooperation between 
aerobic and glycolytic tumor cells against cytotoxic lymphocytes: glycolytic cells take up 
the resources, allowing the tumor to circumvent the immune system and for the more 
successful of the remaining tumor cells to grow (noticeably, these could be either aerobic 
or glycolytic cancer cells; however, the circumvention of the immune system is in this 
case modulated by glycolytic cancer cells). 
The dynamics observed under these parameter values corresponds to the circular 
dynamics predicted in Figure 1. 
Increased immune stimulation can be sufficient to control tumor size but not to 
eliminate it 
Next, we evaluated whether further increases in overall immune stimulation could 
lead to permanent tumor elimination; a positive answer would suggest that tumor growth 
could in some cases be controlled through immunotherapy alone. We observed that 
increasing the value of 
 
i
0
 by five orders of magnitude did not lead to tumor elimination; 
it allowed destabilizing the tumor, yielding oscillatory regimes of a much smaller 
magnitude than in the previous set of simulations, but complete elimination was not 
observed (see Figure 4). 
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Figure 4. Effects of further increases of parameter 0i . The simulations suggest that 
increased immune stimulation can decrease the amplitude of oscillations but cannot yield 
complete tumor elimination. 
 
We then hypothesized that even with strong supplementary immune stimulation, 
tumor elimination can be achieved only if the parameter of tumor elimination 
 
e
j
 is large 
enough (out of parameters that we are choosing to focus on in this paper as the ones that 
can be manipulated in a clinical setting). For this set of simulations, we fixed 
 
i
0
= 2.1e- 4  and then progressively increased parameter 
 
e
j
(see Figure 5).  
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Figure 5. Effects of increases of parameter of tumor elimination je , ,j a g  while 
keeping parameter 0 2.1 4i e  . Calculations suggest that sufficient increases in the 
value of je  can indeed lead to full tumor elimination. 
 
These sets of simulations demonstrate that predictably, high enough rate of killing 
of tumor cells is necessary for tumor elimination. However, if parameter je  cannot be 
manipulated, or increased to a large enough value, higher degree of tumor control would 
be achieved through sufficient immune stimulation, even though it is not expected to 
completely eliminate the tumor regardless of the level of stimulation. 
High death rates of immune cells can promote tumor growth 
Next, we evaluated the effects of high death rates of immune cells on overall 
system dynamics, since cytotoxic therapeutic interventions have adverse effects not only 
on the tumor cells but also on healthy tissues, including cells of the immune system 
(Mackall et al., 1997).  We conducted numerical experiments from the area of phase-
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parameter space where tumor was completely eliminated and then observed the effects of 
increases of parameter 
 
m
I
 on overall system dynamics. Parameters were taken to be 
 
b
T
= 0.9 , 
 
i
0
= 0.0001, 
 
r
g
= 2.8r
a
, 
 
e
a
= e
g
= 0.1; all other parameter values remained the 
same. 
We observed that progressively increasing the values of parameter 
 
m
I
 lead to 
eventual rapid tumor escape, preceded by progressively increasing oscillatory regimes of 
small amplitude (see Figure 6). These results suggest that not only should effects of 
cytotoxic therapies on the immune cells be taken into account but also that immune-
modulated tumor control can be disrupted if the patient is exposed to anything that could 
severely increase mortality of cytotoxic lymphocytes. 
 
Figure 6. This set of calculations illustrates the effect that increased mortality of immune 
cells can have on over all tumor dynamics, ranging from complete elimination (set a) to 
increased destabilizing oscillatory behavior (sets b and c) to tumor escape (set d). Other 
parameters are held constant at 0 1.0 4i e  , 0.9Tb  , 2.8g ar r , 0.1a ge e  . 
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Discussion 
It is conventionally believed that the process of tumor escape from the immune 
system is driven by the eventual mutation induced appearance of non-immunogenic cell 
clones, which allow the cancer to progress unrecognized by the immune system. We 
propose that genomic instability of tumor cells is not imperative for immune escape, 
which can be mediated solely by competition for resources, and specifically glucose, 
between tumor and immune cells in the tumor microenvironment. 
Actively proliferating cells, whether it be tumor or immune cells, up-regulate 
glycolysis as a primary mode of glucose metabolism, both due to its speed compared to 
more efficient but slower oxidative phosphorylation, and due to its ability to provide 
rapidly dividing cells with glycolytic intermediates necessary for biosynthesis of nucleic 
acids (8; 10). This also requires glycolytic cells to overexpress nutrient transporters, such 
as GLUT-1, 20-40 fold compared to aerobic cells, in order to enable the cells to meet 
their energy demands (9; 10). Therefore, it is not unlikely that in the tumor 
microenvironment there must exist some level of competition for glucose between 
actively proliferating cancer and immune cells. 
Such theoretical considerations allow to predict the following dynamics: as the 
tumor grows, cells it its core become oxygen deprived and are forced to switch to 
glycolysis, while the cells on the outer rim of the tumor continue using oxidative 
phosphorylation as a more efficient way to obtain energy. If the aerobic cells on the 
tumor rim are sufficiently immunogenic to initiate a strong immune response, then 
cytotoxic lymphocytes eliminate these cells first, eventually exposing the glycolytic core. 
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Unlike the aerobic tumor cells, glycolytic tumor cells can now present sufficiently strong 
competition to immune cells for glucose, since even the most potent immune cells lose 
the ability to perform their function in the state of nutrient deprivation (11). As a result, 
glycolytic tumor cells can hinder the activity of the immune system solely via 
competition for glucose, allowing tumor escape.  This mechanism is also summarized in 
Figure 1.  
(Interestingly, there exists some evidence of another possible mechanism of 
cooperation between aerobic and glycolytic cells in the tumor, where glycolytic cancer 
cells provide aerobic cells with lactate which they can then utilize as part of the citric acid 
cycle (17);  however, this consideration is not taken into account in the current version of 
the model). 
In order to investigate the variety of possible outcomes of glucose-driven competitive 
interactions between tumor and immune cells, we formulated a mathematical model of 
the type ‘predator-prey-common resource’, where the predator (immune cells) competes 
with the prey (aerobic and glycolytic tumor cells) for the common resources (glucose).  
The proposed 4-dimensional system of ordinary differential equations was solved 
numerically using Matlab2010b. For calculating numerical solutions we focused on 
varying parameters that, at least in theory, can be manipulated in an experimental setting, 
and specifically parameter of overall immune stimulation 
 
i
0
, parameter of the 
effectiveness of tumor elimination by immune cells  e and parameter of immune cell 
mortality 
 
m
I
; all the parameter values used are given in the text. 
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First we varied parameter 0i , which in our model represents systemic immune 
stimulation and which in an experimental setting could be influenced positively by 
immunotherapy or negatively by tumor-induced immune suppression. We indeed were 
able to observe the theoretically predicted cyclical dynamics (see Figure 2). As tumor 
size decreased, so did the population of immune cells, since co-stimulatory molecules 
from tumor debris were required for clonal expansion of immune cells.  As the 
population of immune cells decreased, glucose levels rose, which made it available to the 
expanding population of glycolytic tumor cells. This in turn caused a sharp drop in 
glucose levels in the tumor microenvironment, preventing immune cells from 
proliferating. The details of this interaction are visualized on Figure 3a. Moreover, we 
showed that such cyclical dynamics could in fact occur several times before the tumor 
either shrinks or escapes.  
Next, we wanted to investigate whether the tumor can be eliminated through 
increased stimulation of the immune system alone, i.e., whether one could expect to cure 
the disease solely via extensive immune stimulation, such as through immunotherapy. 
We observed that increasing immune stimulation by five orders of magnitude still did not 
yield complete tumor elimination. Only sufficiently increased killing of the tumor cells 
by the immune system was shown to lead to complete tumor elimination (see Figure 5). 
These results suggest that immunotherapy could be an effective complementary therapy 
but it should not normally be expected to cure the cancer.  
Finally, we evaluated the impact of high death rates of immune cells on overall tumor 
dynamics, since this parameter can be influenced both acutely as a side effect of 
cytotoxic therapies (18-21) and chronically via environmental factors, such as low-dose 
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radiation (unpublished data obtained in our lab); some studies also suggest that 
lymphocyte count recovery after anti-cancer treatment with cytotoxic drugs can serve as a 
predictor of superior survival in AML and ALL patients (22-24). As expected, we 
observed that progressively increasing parameter of immune cell mortality lead to 
eventual tumor escape, preceded by progressively increasing oscillatory regimes of small 
amplitude (see Figure 6), suggesting that immune cell mortality could be another 
dimension along which predicted therapy efficacy should be evaluated. 
From the point of view of therapeutic implications, the proposed theoretical model of 
glucose-modulated immunoediting can provide an explanation for limited success of 
immunotherapy as a mode of treatment (25; 26).: even activated cytotoxic lymphocytes, 
such as those obtained via adoptive T cell transfer, would not be able to undergo clonal 
expansion and perform their function if glycolytic tumor cells consume the resources 
from the tumor microenvironment. At the same time, vaccine therapies, which have 
shown most promise, provide systemic immune stimulation, which, as the model 
predicts, can be of crucial importance for maintaining tumor size at a controlled level (27; 
28). 
More generally, the proposed theoretical construct provides an additional explanation 
for persistence of fast but inefficient aerobic glycolysis observed in many tumors, a 
phenomenon also known as Warburg effect (5). Not only can up-regulated glycolysis 
provide building materials for actively growing cells (8) and promote successful 
competition with somatic cells through creating an acidic microenvironment (29-31) but 
it can also allow tumor cells to circumvent the immune system via competition for 
nutrients. 
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Intriguingly, from this point of view, very strong immune response could in fact 
promote tumor progression, since these cells would be more efficient at exposing the 
tumor’s glycolytic core. Therefore, it is the moderately strong immune stimulation that 
would be able to most successfully control tumor growth. This prediction would 
correspond to predictions made by both in silico and in vivo experiments conducted by 
Gatenby et al. (Cancer Res 2009), where the authors demonstrate that a therapeutic set-
up, in which chemotherapeutic treatment was continuously modulated to achieve a fixed 
tumor population, allowed mice to coexist with the tumors indefinitely. The authors 
suggested that best results in the long term could be achieved by permitting a significant 
population of chemo-sensitive cells to survive so that they, in turn, suppress proliferation 
of the less fit but chemo-resistant subpopulations (32). Moderately but not excessively 
effective immune response would present a natural example of such an adaptive therapy, 
which can help better understand and improve existing immunotherapies. 
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Table 1. Variables and parameters used in System 1. Variables are cast in units of 
biomass; rates are cast in units 1/time.  
 Description Sample value Source 
( )T t
 
Population of tumor cells, composed of 
aerobic ( )aT t  and glycolytic ( )gT t  cells  
( ) 0T t   est. 
( )G t
 
Glucose ( ) 0G t   est. 
( )I t
 
Cytotoxic immune cells ( ) 0I t   est. 
ar  Growth rate of aerobic cancer cells  4.31´10
-1 De pillis06 
gr  Growth rate of glycolytic cancer cells 1 1, [0.5,5.0]ar k k   est. 
a  Natural death rate or aerobic cancer cells 0.01 est. 
g  Natural death rate of glycolytic cancer cells 2 2, [1.0,10.0]g k k 
 
est. 
ae  Fractional aerobic cell kill by immune cells 0.1 est. 
ge  Fractional glycolytic cell kill by immune 
cells 
3 3, [ 0.1,0.1]ae k k  
 
est. 
s  Steepness coefficient of the tumor cell kill by 
immune cells 
16.18 10  dePillis05 
0G  Rate of glucose inflow into tumor 
microenvironment from blood stream 
0 [0.1,10.0]G   est. 
g  Rate of glucose outflow from tumor 
microenvironment from blood stream 
0.01 est. 
ad  Rate of glucose consumption by aerobic 
tumor cells 
0.1 est. 
gd  Rate of glucose consumption by glycolytic 
tumor cells 
4 4, [1.0,30.0]ad k k 
 
Ganapathy09 
Id  Rate of glucose consumption by the immune 
cells 
I ad d  Fox05 
0i  Rate of tumor-stimulated inflow of immune 
cells 
0 [.001,0.100]i   n/a 
I  Death rate of immune cells 
22.0 10  dePillis05 
Ir  Rate at which immune cells are stimulated to 
be produced as a result of coming in contact 
with tumor debris from previously killed 
tumor cells 
11.13 10  De pillis05 
 
